Clinuvel Pharmaceuticals Ltd
ASX:CUV

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Watchlist
Price: 12.15 AUD 0.33% Market Closed
Market Cap: 608.2m AUD
Have any thoughts about
Clinuvel Pharmaceuticals Ltd?
Write Note

Clinuvel Pharmaceuticals Ltd
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Clinuvel Pharmaceuticals Ltd
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Clinuvel Pharmaceuticals Ltd
ASX:CUV
PP&E Net
AU$7.7m
CAGR 3-Years
44%
CAGR 5-Years
61%
CAGR 10-Years
53%
Immutep Ltd
ASX:IMM
PP&E Net
AU$679.7k
CAGR 3-Years
30%
CAGR 5-Years
67%
CAGR 10-Years
2%
Mesoblast Ltd
ASX:MSB
PP&E Net
$3.8m
CAGR 3-Years
-32%
CAGR 5-Years
36%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
PP&E Net
$9.7B
CAGR 3-Years
9%
CAGR 5-Years
17%
CAGR 10-Years
18%
Telix Pharmaceuticals Ltd
ASX:TLX
PP&E Net
AU$30.5m
CAGR 3-Years
85%
CAGR 5-Years
167%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
PP&E Net
AU$1.6m
CAGR 3-Years
2%
CAGR 5-Years
27%
CAGR 10-Years
17%
No Stocks Found

Clinuvel Pharmaceuticals Ltd
Glance View

Market Cap
608.4m AUD
Industry
Biotechnology

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.

CUV Intrinsic Value
20.89 AUD
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Clinuvel Pharmaceuticals Ltd's PP&E Net?
PP&E Net
7.7m AUD

Based on the financial report for Jun 30, 2024, Clinuvel Pharmaceuticals Ltd's PP&E Net amounts to 7.7m AUD.

What is Clinuvel Pharmaceuticals Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
53%

Over the last year, the PP&E Net growth was 171%. The average annual PP&E Net growth rates for Clinuvel Pharmaceuticals Ltd have been 44% over the past three years , 61% over the past five years , and 53% over the past ten years .

Back to Top